Cagrilintide 5mg
Cagrilintide is a long-acting, acylated analogue of amylin developed by Novo Nordisk. It activates the amylin receptors AMY1, AMY2 and AMY3, which take part in appetite regulation, gastric emptying and glucose homeostasis. Supplied for laboratory research use only. Not for human or veterinary use.
A long-acting amylin analogue, for metabolic research.
Cagrilintide is a long-acting, acylated analogue of amylin developed by Novo Nordisk. It activates the amylin receptors AMY1, AMY2 and AMY3, which take part in appetite regulation, gastric emptying and glucose homeostasis.
What the research shows
Studies have examined satiety signalling and body-weight regulation. Acylation extends the half-life enough for once-weekly dosing in clinical studies.
Phase 2 trials have tested cagrilintide alone and alongside semaglutide, with published data on appetite, body composition and metabolic measures.
Why researchers choose Aevryn Labs
Every batch is tested at a leading Australian university, where HPLC and mass spectrometry confirm a purity of 99% or higher. No generic overseas certificates.
Explore the research library
